Michael von Bergwelt-Baildon

39PUBLICATIONS
269CO-AUTHORS
Haematological tumoursHaematologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Aug 24, 2026
TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

|Jun 30, 2026
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

|Jun 01, 2026
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

|Dec 04, 2025
TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.

Monika Sponheimer, Kieron White, Michelle Ulrich

|Aug 26, 2025
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma.

Michael Winkelmann, Sandeep S Raj, Michael D Jain

|May 27, 2025
Clinical features, course, and risk factors of infection-associated secondary hemophagocytic lymphohistiocytosis.

Michael Ruzicka, Thomas Wimmer, Hans-Joachim Stemmler

Pageof 7

Frequent Collaborators

12 joint publications

Veit L Buecklein

10 joint publications

Kai Rejeski

6 joint publications

Michael D Jain

6 joint publications

Karsten Spiekermann